Agree. If 10% market share is already giving us A$0.89 per share, imagine 30% or 50%... They also applied a 30% probability on future cashflows post commercialization so I assume the NPV will be more than tripled if the drug does get approved for ALS/MND.
Ann: PharmAust Partners with Berry Consultants for MND Phase 2/3, page-33
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.010(4.88%) |
Mkt cap ! $94.79M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 19.5¢ | $188.9K | 946.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 800531 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 49199 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |